Optimization of combined antitumor chemotherapy with bevacizumab by means of mathematical modeling
DOI10.1007/978-3-319-91092-5_24zbMATH Open1401.92106OpenAlexW2886419849MaRDI QIDQ4556944FDOQ4556944
Authors: M. B. Kuznetsov, A. V. Kolobov
Publication date: 28 November 2018
Published in: Trends in Biomathematics: Modeling, Optimization and Computational Problems (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1007/978-3-319-91092-5_24
Recommendations
- Mathematical modelling of chemotherapy combined with bevacizumab
- The study of antitumor efficacy of bevacizumab antiangiogenic therapy using a mathematical model
- Mathematical modeling in scheduling cancer treatment with combination of VEGF inhibitor and chemotherapy drugs
- A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
- Optimizing the delivery of combination therapy for tumors: A mathematical model
Medical applications (general) (92C50) PDEs in connection with biology, chemistry and other natural sciences (35Q92)
Cites Work
Cited In (7)
- Optimizing the delivery of combination therapy for tumors: A mathematical model
- Mathematical modelling of chemotherapy combined with bevacizumab
- Analysis of anticancer efficiency of combined fractionated radiotherapy and antiangiogenic therapy via mathematical modelling
- The study of antitumor efficacy of bevacizumab antiangiogenic therapy using a mathematical model
- Theoretical investigation of the efficacy of antiangiogenic drugs combined to chemotherapy in xenografted mice
- A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology
- Mathematical modeling in scheduling cancer treatment with combination of VEGF inhibitor and chemotherapy drugs
This page was built for publication: Optimization of combined antitumor chemotherapy with bevacizumab by means of mathematical modeling
Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4556944)